Overview

Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia

Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
To determine the safety & efficacy of brexpiprazole monotherapy in the treatment of adolescents with schizophrenia.
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborator:
H. Lundbeck A/S
Treatments:
Aripiprazole
Brexpiprazole